Mavacamten

Mavacamten is an orally bioavailable inhibitor of cardiac myosin ATPase (IC50 = 0.3 µM in purified bovine myosin S1). It is selective for cardiac myosin over skeletal myosin (IC50 = 4.7 µM) and does not induce skeletal muscle impairments. It slows the rate of ATPase activity in both murine and bovine myofibrils, which are alpha- and beta-myosin-rich, respectively, by reducing the rate of phosphate release during the myosin power stroke. In transgenic mouse models of hypertrophic cardiomyopathy, mavacamten reduces cardiac contractility, prevents left ventricular hypertrophy, and reverses pathologic remodeling. In cats, it relieves left ventricular outflow tract obstruction. Formulations containing mavacamten have been used for the treatment of symptomatic hypertrophic cardiomyopathy in humans and cats.Formal Name: 3-(1-methylethyl)-6-[[(1S)-1-phenylethyl]amino]-2,4(1H,3H)-pyrimidinedione. CAS Number: 1642288-47-8. Synonyms: MYK-461, SAR439152. Molecular Formula: C15H19N3O2. Formula Weight: 273.3. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 33 mg/ml, DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml, DMSO: 20 mg/ml, Ethanol: 1 mg/ml. lambdamax: 267 nm. SMILES: O=C1N(C(C)C)C(NC(N[C@@H](C)C2=CC=CC=C2)=C1)=O. InChi Code: InChI=1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1. InChi Key: RLCLASQCAPXVLM-NSHDSACASA-N.